Connect with us

Hi, what are you looking for?

Economy

Eli Lilly’s antibody combination receives FDA emergency use authorization for COVID-19

Image of Eli Lilly Corporate Center, Indianapolis, Indiana, via Wikimedia Commons / CC BY-SA 4.0

Eli Lilly’s combination antibody therapy to fight COVID-19 has been granted emergency use authorization by the US Food and Drug Administration (FDA), Lilly said on Tuesday.

Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January.

Lilly said the therapy will be available immediately.

“There are 100,000 doses ready immediately and an additional 150,000 doses will be available throughout the first quarter,” Lilly said in a statement.

The company said that in collaboration with Amgen, it plans to manufacture up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021.

Lilly said the “therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.”

The FDA, separately, said bamlanivimab and etesevimab are not authorized for patients hospitalized due to COVID-19 or who require oxygen therapy due to COVID-19.

Late last month, Lilly reported a fourth-quarter profit that topped Wall Street estimates. It recorded $871.2 million in quarterly sales of the COVID-19 therapy bamlanivimab, benefiting from the US government’s move to stock up on the drug for emergency use. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Investing

Biography-writing service StoryTerrace has announced a unique partnership with UKTV in a £1 million ‘airtime-for-equity’ deal. The deal will see StoryTerrace launch its first television...

Economy

(Part 3) When the Senators start to deliberate on the Maharlika Investment Fund, they should make it a point to avoid wasting their time...

Economy

United States Defense Secretary Lloyd Austin III, during his visit to Manila last week, reaffirmed his country’s commitment to help the Philippines strengthen its...

Economy

FOR THOSE BETTING against the world’s ability to kick its carbon addiction, the commodities boom of the past few years has provided fresh ammunition....

Investing

New research has revealed the damaging effect that strikes are having on the sector, with 14% of SME owners saying they have negatively impacted...

Economy

ANTAKYA, Turkey — Overwhelmed rescuers struggled to save people trapped under the rubble as the death toll from a devastating earthquake in Turkey and...

You May Also Like

Investing

Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...

Investing

The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.